Keap1/Nrf2 pathway in kidney cancer

Frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma

Federico Pio Fabrizio, Manuela Costantini, Massimiliano Copetti, Annamaria la Torre, Angelo Sparaneo, Andrea Fontana, Luana Poeta, Michele Gallucci, Steno Sentinelli, Paolo Graziano, Paola Parente, Vincenzo Pompeo, Laura De Salvo, Giuseppe Simone, Rocco Papalia, Francesco Picardo, Teresa Balsamo, Gerardo Paolo Flammia, Domenico Trombetta, Angela Pantalone & 4 others Klaas Kok, Ferronika Paranita, L. A. Muscarella, Vito Michele Fazio

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The Keap1/Nrf2 pathway is a master regulator of the cellular redox state through the induction of several antioxidant defence genes implicated in chemotherapeutic drugs resistance of tumor cells. An increasing body of evidence supports a key role for Keap1/Nrf2 pathway in kidney diseases and renal cell carcinoma (RCC), but data concerning the molecular basis and the clinical effect of its deregulation remain incomplete. Here we present a molecular profiling of the KEAP1 and NFE2L2 genes in five different Renal Cell Carcinoma histotypes by analysing 89 tumor/normal paired tissues (clear cell Renal Carcinoma, ccRCCs; Oncocytomas; Papillary Renal Cell Carcinoma Type 1, PRCC1; Papillary Renal Cell Carcinoma Type 2, PRCC2; and Chromophobe Cell Carcinoma). A tumor-specific DNA methylation of the KEAP1 gene promoter region was found as a specific feature of the ccRCC subtype (18/37, 48.6%) and a direct correlation with mRNA levels was confirmed by in vitro 5-azacytidine treatment. Analysis of an independent data set of 481 ccRCC and 265 PRCC tumors corroborates our results and multivariate analysis reveals a significant correlation among ccRCCs epigenetic KEAP1 silencing and staging, grading and overall survival. Our molecular results show for the the first time the epigenetic silencing of KEAP1 promoter as the leading mechanism for modulation of KEAP1 expression in ccRCCs and corroborate the driver role of Keap1/Nrf2 axis deregulation with potential new function as independent epigenetic prognostic marker in renal cell carcinoma.

Original languageEnglish
Pages (from-to)11187-11198
Number of pages12
JournalOncotarget
Volume8
Issue number7
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Methylation
Epigenomics
Genes
Neoplasms
Oxyphilic Adenoma
Azacitidine
Kidney Diseases
DNA Methylation
Drug Resistance
Genetic Promoter Regions
Oxidation-Reduction
Multivariate Analysis
Antioxidants
Carcinoma
Messenger RNA

Keywords

  • ccRCC
  • Epigenetic biomarker
  • KEAP1
  • Methylation
  • Outcome

ASJC Scopus subject areas

  • Oncology

Cite this

Keap1/Nrf2 pathway in kidney cancer : Frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. / Fabrizio, Federico Pio; Costantini, Manuela; Copetti, Massimiliano; la Torre, Annamaria; Sparaneo, Angelo; Fontana, Andrea; Poeta, Luana; Gallucci, Michele; Sentinelli, Steno; Graziano, Paolo; Parente, Paola; Pompeo, Vincenzo; Salvo, Laura De; Simone, Giuseppe; Papalia, Rocco; Picardo, Francesco; Balsamo, Teresa; Flammia, Gerardo Paolo; Trombetta, Domenico; Pantalone, Angela; Kok, Klaas; Paranita, Ferronika; Muscarella, L. A.; Fazio, Vito Michele.

In: Oncotarget, Vol. 8, No. 7, 01.01.2017, p. 11187-11198.

Research output: Contribution to journalArticle

Fabrizio, FP, Costantini, M, Copetti, M, la Torre, A, Sparaneo, A, Fontana, A, Poeta, L, Gallucci, M, Sentinelli, S, Graziano, P, Parente, P, Pompeo, V, Salvo, LD, Simone, G, Papalia, R, Picardo, F, Balsamo, T, Flammia, GP, Trombetta, D, Pantalone, A, Kok, K, Paranita, F, Muscarella, LA & Fazio, VM 2017, 'Keap1/Nrf2 pathway in kidney cancer: Frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma', Oncotarget, vol. 8, no. 7, pp. 11187-11198. https://doi.org/10.18632/oncotarget.14492
Fabrizio, Federico Pio ; Costantini, Manuela ; Copetti, Massimiliano ; la Torre, Annamaria ; Sparaneo, Angelo ; Fontana, Andrea ; Poeta, Luana ; Gallucci, Michele ; Sentinelli, Steno ; Graziano, Paolo ; Parente, Paola ; Pompeo, Vincenzo ; Salvo, Laura De ; Simone, Giuseppe ; Papalia, Rocco ; Picardo, Francesco ; Balsamo, Teresa ; Flammia, Gerardo Paolo ; Trombetta, Domenico ; Pantalone, Angela ; Kok, Klaas ; Paranita, Ferronika ; Muscarella, L. A. ; Fazio, Vito Michele. / Keap1/Nrf2 pathway in kidney cancer : Frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. In: Oncotarget. 2017 ; Vol. 8, No. 7. pp. 11187-11198.
@article{f265adb063684684858d5a0556d24156,
title = "Keap1/Nrf2 pathway in kidney cancer: Frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma",
abstract = "The Keap1/Nrf2 pathway is a master regulator of the cellular redox state through the induction of several antioxidant defence genes implicated in chemotherapeutic drugs resistance of tumor cells. An increasing body of evidence supports a key role for Keap1/Nrf2 pathway in kidney diseases and renal cell carcinoma (RCC), but data concerning the molecular basis and the clinical effect of its deregulation remain incomplete. Here we present a molecular profiling of the KEAP1 and NFE2L2 genes in five different Renal Cell Carcinoma histotypes by analysing 89 tumor/normal paired tissues (clear cell Renal Carcinoma, ccRCCs; Oncocytomas; Papillary Renal Cell Carcinoma Type 1, PRCC1; Papillary Renal Cell Carcinoma Type 2, PRCC2; and Chromophobe Cell Carcinoma). A tumor-specific DNA methylation of the KEAP1 gene promoter region was found as a specific feature of the ccRCC subtype (18/37, 48.6{\%}) and a direct correlation with mRNA levels was confirmed by in vitro 5-azacytidine treatment. Analysis of an independent data set of 481 ccRCC and 265 PRCC tumors corroborates our results and multivariate analysis reveals a significant correlation among ccRCCs epigenetic KEAP1 silencing and staging, grading and overall survival. Our molecular results show for the the first time the epigenetic silencing of KEAP1 promoter as the leading mechanism for modulation of KEAP1 expression in ccRCCs and corroborate the driver role of Keap1/Nrf2 axis deregulation with potential new function as independent epigenetic prognostic marker in renal cell carcinoma.",
keywords = "ccRCC, Epigenetic biomarker, KEAP1, Methylation, Outcome",
author = "Fabrizio, {Federico Pio} and Manuela Costantini and Massimiliano Copetti and {la Torre}, Annamaria and Angelo Sparaneo and Andrea Fontana and Luana Poeta and Michele Gallucci and Steno Sentinelli and Paolo Graziano and Paola Parente and Vincenzo Pompeo and Salvo, {Laura De} and Giuseppe Simone and Rocco Papalia and Francesco Picardo and Teresa Balsamo and Flammia, {Gerardo Paolo} and Domenico Trombetta and Angela Pantalone and Klaas Kok and Ferronika Paranita and Muscarella, {L. A.} and Fazio, {Vito Michele}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14492",
language = "English",
volume = "8",
pages = "11187--11198",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "7",

}

TY - JOUR

T1 - Keap1/Nrf2 pathway in kidney cancer

T2 - Frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma

AU - Fabrizio, Federico Pio

AU - Costantini, Manuela

AU - Copetti, Massimiliano

AU - la Torre, Annamaria

AU - Sparaneo, Angelo

AU - Fontana, Andrea

AU - Poeta, Luana

AU - Gallucci, Michele

AU - Sentinelli, Steno

AU - Graziano, Paolo

AU - Parente, Paola

AU - Pompeo, Vincenzo

AU - Salvo, Laura De

AU - Simone, Giuseppe

AU - Papalia, Rocco

AU - Picardo, Francesco

AU - Balsamo, Teresa

AU - Flammia, Gerardo Paolo

AU - Trombetta, Domenico

AU - Pantalone, Angela

AU - Kok, Klaas

AU - Paranita, Ferronika

AU - Muscarella, L. A.

AU - Fazio, Vito Michele

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The Keap1/Nrf2 pathway is a master regulator of the cellular redox state through the induction of several antioxidant defence genes implicated in chemotherapeutic drugs resistance of tumor cells. An increasing body of evidence supports a key role for Keap1/Nrf2 pathway in kidney diseases and renal cell carcinoma (RCC), but data concerning the molecular basis and the clinical effect of its deregulation remain incomplete. Here we present a molecular profiling of the KEAP1 and NFE2L2 genes in five different Renal Cell Carcinoma histotypes by analysing 89 tumor/normal paired tissues (clear cell Renal Carcinoma, ccRCCs; Oncocytomas; Papillary Renal Cell Carcinoma Type 1, PRCC1; Papillary Renal Cell Carcinoma Type 2, PRCC2; and Chromophobe Cell Carcinoma). A tumor-specific DNA methylation of the KEAP1 gene promoter region was found as a specific feature of the ccRCC subtype (18/37, 48.6%) and a direct correlation with mRNA levels was confirmed by in vitro 5-azacytidine treatment. Analysis of an independent data set of 481 ccRCC and 265 PRCC tumors corroborates our results and multivariate analysis reveals a significant correlation among ccRCCs epigenetic KEAP1 silencing and staging, grading and overall survival. Our molecular results show for the the first time the epigenetic silencing of KEAP1 promoter as the leading mechanism for modulation of KEAP1 expression in ccRCCs and corroborate the driver role of Keap1/Nrf2 axis deregulation with potential new function as independent epigenetic prognostic marker in renal cell carcinoma.

AB - The Keap1/Nrf2 pathway is a master regulator of the cellular redox state through the induction of several antioxidant defence genes implicated in chemotherapeutic drugs resistance of tumor cells. An increasing body of evidence supports a key role for Keap1/Nrf2 pathway in kidney diseases and renal cell carcinoma (RCC), but data concerning the molecular basis and the clinical effect of its deregulation remain incomplete. Here we present a molecular profiling of the KEAP1 and NFE2L2 genes in five different Renal Cell Carcinoma histotypes by analysing 89 tumor/normal paired tissues (clear cell Renal Carcinoma, ccRCCs; Oncocytomas; Papillary Renal Cell Carcinoma Type 1, PRCC1; Papillary Renal Cell Carcinoma Type 2, PRCC2; and Chromophobe Cell Carcinoma). A tumor-specific DNA methylation of the KEAP1 gene promoter region was found as a specific feature of the ccRCC subtype (18/37, 48.6%) and a direct correlation with mRNA levels was confirmed by in vitro 5-azacytidine treatment. Analysis of an independent data set of 481 ccRCC and 265 PRCC tumors corroborates our results and multivariate analysis reveals a significant correlation among ccRCCs epigenetic KEAP1 silencing and staging, grading and overall survival. Our molecular results show for the the first time the epigenetic silencing of KEAP1 promoter as the leading mechanism for modulation of KEAP1 expression in ccRCCs and corroborate the driver role of Keap1/Nrf2 axis deregulation with potential new function as independent epigenetic prognostic marker in renal cell carcinoma.

KW - ccRCC

KW - Epigenetic biomarker

KW - KEAP1

KW - Methylation

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=85012878891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012878891&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14492

DO - 10.18632/oncotarget.14492

M3 - Article

VL - 8

SP - 11187

EP - 11198

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 7

ER -